U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

Lee Munson, president and CIO at Portfolio Wealth Advisors, joins CNBC’s ‘Power Lunch’ to discuss outlooks on three stocks: ...

Pregame analysis and predictions of the Sacred Heart Pioneers vs. Brown Bears NCAAM game to be played on November 17, 2024 on ...

Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type ...

Diane Brady: Leadership Next is powered by the folks at Deloitte who, like me, are exploring the changing roles of business ...

One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

Should you forget Eli Lilly and buy this magnificent biotech instead? Let's find out.

In today's biotech news, Zepbound trial data, Regenxbio's Duchenne muscular dystrophy treatment, and Intellia's promising ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...